Skip to main content
James Blachly, MD, Hematology, Columbus, OH, Ohio State University Wexner Medical Center

JamesStewartBlachlyMD

Hematology • Columbus, OH

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Tenured Associate Professor of Medicine. Leader of OSU Hereditary Hematologic Neoplasm Program and HALT Clinic Co-Director. Director of Sequencing at OSU Experimental Hematology Lab. Co-Chair of Alliance A-STOR.

Join to view full profile

Dr. Blachly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Blachly's full profile

Already have an account?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Arkansas for Medical Sciences (UAMS) College of Medicine
    University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2007 - 2011
  • University of Arkansas For Medical Sciences College of Medicine
    University of Arkansas For Medical Sciences College of MedicineClass of 2007

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2011 - 2025
  • AR State Medical License
    AR State Medical License 2010 - 2023

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
    Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

  • Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing
    James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Editorial Roundup: Pennsylvania
    Editorial Roundup: PennsylvaniaAugust 21st, 2021
  • NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines Updates
    NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines UpdatesMarch 29th, 2017

Hospital Affiliations

Dr. James Blachly, Dr. James Blachly, MD, Dr. J Blachly, Dr. James Stewart Blachly